JP2024541701A5 - - Google Patents

Info

Publication number
JP2024541701A5
JP2024541701A5 JP2024553275A JP2024553275A JP2024541701A5 JP 2024541701 A5 JP2024541701 A5 JP 2024541701A5 JP 2024553275 A JP2024553275 A JP 2024553275A JP 2024553275 A JP2024553275 A JP 2024553275A JP 2024541701 A5 JP2024541701 A5 JP 2024541701A5
Authority
JP
Japan
Prior art keywords
domain
cso
ribonucleotide
modified
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541701A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/044406 external-priority patent/WO2023049275A2/en
Publication of JP2024541701A publication Critical patent/JP2024541701A/ja
Publication of JP2024541701A5 publication Critical patent/JP2024541701A5/ja
Pending legal-status Critical Current

Links

JP2024553275A 2021-09-23 2022-09-22 治療剤としての環状構造化オリゴヌクレオチド Pending JP2024541701A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163247556P 2021-09-23 2021-09-23
US63/247,556 2021-09-23
PCT/US2022/044406 WO2023049275A2 (en) 2021-09-23 2022-09-22 Cyclic structured oligonucleotides as therapeutic agents

Publications (2)

Publication Number Publication Date
JP2024541701A JP2024541701A (ja) 2024-11-08
JP2024541701A5 true JP2024541701A5 (cg-RX-API-DMAC7.html) 2025-09-25

Family

ID=85721143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553275A Pending JP2024541701A (ja) 2021-09-23 2022-09-22 治療剤としての環状構造化オリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20250270550A1 (cg-RX-API-DMAC7.html)
EP (1) EP4405482A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541701A (cg-RX-API-DMAC7.html)
KR (1) KR20240082367A (cg-RX-API-DMAC7.html)
CN (1) CN118284697A (cg-RX-API-DMAC7.html)
CA (1) CA3174342A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023049275A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260005403A (ko) * 2023-03-22 2026-01-09 아르네이 사이언시스 엘엘씨 원형 프로드럭 핵산을 이용한 rna 치료제의 전달
EP4731768A2 (en) * 2023-06-23 2026-04-29 Arnay Sciences, Llc Delivery of rna therapeutics using ring-shaped nucleic acids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658738A (en) * 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
ES2109177B1 (es) * 1995-10-11 1998-07-16 Univ Barcelona Procedimiento general de preparacion de oligonucleotidos ciclicos e intermedios para el mismo.
US6383752B1 (en) * 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
EP1316607A1 (en) * 1999-03-31 2003-06-04 Hybridon, Inc. Pseudo-cyclic oligonucleobases for inhibiting tumor growth
AU770615B2 (en) * 1999-03-31 2004-02-26 Hybridon, Inc. Pseudo-cyclic oligonucleobases
JP3976742B2 (ja) * 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
FR2933410B1 (fr) * 2008-07-04 2010-08-20 Biomerieux Sa Nouvelle sonde de detection
WO2010084371A1 (en) * 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
WO2012102616A1 (en) * 2011-01-28 2012-08-02 Flexgen B.V. Heterodirectional polynucleotides
US20140128449A1 (en) * 2011-04-07 2014-05-08 The Board Of Regents Of The University Of Texas System Oligonucleotide modulation of splicing
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso

Similar Documents

Publication Publication Date Title
JP5805088B2 (ja) 遺伝子発現を阻害する組成物およびその使用
Wagner et al. Potent and selective inhibition of gene expression by an antisense heptanucleotide
JP5669897B2 (ja) Tlr7およびtlr8に対する安定化免疫調節rna(simra)化合物
TWI695066B (zh) 用於抑制b型肝炎病毒基因表現之組合物及方法
CN1604795B (zh) 具有提高的活性的组合基序免疫刺激寡肽
US8552167B2 (en) Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
US20110059067A1 (en) Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
JPH08510900A (ja) 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド
US7060690B2 (en) Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
JP2009521208A (ja) ヒトil−12サイトカインファミリーに対するアプタマーおよびその自己免疫関連疾患治療薬としての使用
JP2008514647A (ja) 二本鎖リボ核酸によって炎症性疾患を治療する方法
CN102686729A (zh) 用于治疗hsf1相关疾病的有机组合物
US20230340496A1 (en) Aptamer template and method for preparing aptamer by using same
TW201919654A (zh) 用於抑制α-ENaC表現之RNAi試劑及使用方法
KR20110017005A (ko) Tgf-베타 수용체 유전자 발현 억제용 조성물 및 방법
CN114846142A (zh) 用于抑制β-ENaC表达的RNAi试剂、其组合物和使用方法
CN112055598A (zh) 用于抑制gys2表达的组合物和方法
JP2007527246A (ja) ヒトil−12サイトカインファミリーに対するアプタマーおよび自己免疫疾患の治療剤としてのそれらの使用
US20030203356A1 (en) RNase L activator-antisense complexes
US7910563B2 (en) Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA
CN103597075A (zh) 用于选择性地杀伤细胞的生物活性核苷酸分子、其用途及应用试剂盒
KR101986705B1 (ko) 압타머 제조 방법
AU781297B2 (en) Chimeric DNA/RNA ribozymes containing propanediol
JP2024516575A5 (cg-RX-API-DMAC7.html)
JP2024526189A (ja) 予防および治療のためのg-四重鎖含有オリゴヌクレオチド